Medifast Appoints Nicholas Johnson as CEO Effective June 1, 2026
MED•Medifast will appoint Nicholas Johnson as CEO on June 1, 2026, succeeding Dan Chard who remains board chairman under a formal leadership transition plan. Johnson, serving as President since early 2026 and with roles since 2018, led the company’s coach-led model and unified business strategy.
1. CEO Succession Details
Nicholas Johnson will become CEO on June 1, 2026, succeeding Dan Chard, who will continue as chairman of the board with strategic oversight under the company’s formal transition plan disclosed in January.
2. Johnson’s Leadership Background
Johnson joined Medifast in 2018 as Market President of OPTAVIA USA and advanced through roles including President of Coach and Client Experience in 2020, Chief Field Operations Officer in 2022 and President in early 2026, driving growth in the coach-led model.
3. Transition Plan and Strategy Outlook
The board’s leadership plan seeks to ensure continuity as Medifast refines its comprehensive metabolic health approach, with Johnson set to leverage evidence-based science and an independent coach network to expand client reach and sustainable outcomes.
